中科院化学所王铁团队开发了用于复杂生物泪液中准确诊断黄疸的分离传感平台。相关研究成果于2022年5月12日发表在《德国应用化学》。

泪液中生物标志物的检测因其无创性和快速采集的优点而引起了人们的极大兴趣。表面增强拉曼光谱（SERS）传感器的超灵敏和无标记检测的结合有望在家庭医疗保健中实现实时诊断。然而，SERS传感器的表面容易受到眼泪中生物杂质的生物污染和失活，导致灵敏度迅速降低，从而限制了护理点设备的商业化。

该文中，研究人员构建了一个具有双重性质的二元纳米球阵列，作为诊断泪液中目标分子的分离传感平台。该结构的上部由Au纳米颗粒（AuNPs）和溅射的Au层组成，Au层可以结合与Au相互作用的目标分子，并提供高强度和高密度的SERS热点。下半部分为非活性SiO₂纳米球阵列，具有周期性的大孔，能够使生物杂质穿透下半部分并与目标分析物分离。此外，这种基质被整合到自制的泪液试剂盒中，可以同时收集、预分离和检测泪液。结合泪液的拉曼光谱和LDA分析，研究人员在临床上成功地鉴别出黄疸患者。

该平台有望为基于生物流体的早期疾病筛查提供机会。

附：英文原文

Title: A Separation-Sensing Platform Performing Accurate Diagnosis of Jaundice in Complex Biological Tear Fluids

Author: Weidong Zhao, Jinming Li, Zhenjie Xue, Xuezhi Qiao, Ailin Li, Xiangyu Chen, Yun Feng, Tie Wang

Issue&Volume: 2022-05-12

Abstract: The detection of biomarkers in tears has aroused great interest owing to the advantages of non-invasive and rapid collection. The combination of ultrasensitivity and label-free detection of surface-enhanced Raman spectroscopy (SERS) sensors is expected to achieve real-time diagnosis in home medical care. However, the surface of SERS sensors is susceptible to biofouling and inactivation by biological impurities in tears, resulting in rapid degradation of sensitivity, limiting the commercialization of point-of-care devices. Herein, a binary nanosphere array with dual properties is constructed as a separation-sensing platform for the diagnosis of target molecules in tears. The upper part of the structure is composed of Au nanoparticles (AuNPs) and a sputtering Au layer, which can bind the target molecules that interact with Au and provide high-strength and high-density SERS hotspots. The lower half is an inactive SiO  2  nanosphere array with periodic large pores that allows biological impurities to penetrate the lower part and be separated from the target analyte. Furthermore, this substrate was integrated into homemade tear kits, enabling simultaneous tear collection, pre-separation, and detection. Combined with the Raman spectra of tears and LDA analysis, we successfully identified patients with jaundice in clinics. This platform is expected to provide an opportunity for early disease screening based on biological fluids.

DOI: 10.1002/anie.202205628

Source: https://onlinelibrary.wiley.com/doi/10.1002/anie.202205628